Sponsor study identifier
interventional
144
1 country
1
Study Start
July 12, 2026
Actual (reported)Primary Completion
September 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Endoscopic sinus surgery (ESS) is a primary surgical approach for treating chronic rhinosinusitis, nasal polyps, and other conditions that are unresponsive to conservative therapy. A clear surgical field is a critical prerequisite for ensuring precision, efficiency, and the avoidance of injury to vital structures such as the orbit and the skull base. Currently, the anesthetic regimens commonly used for ESS include total intravenous anesthesia (TIVA), inhalational anesthesia (IA), and intravenous-inhalational combined anesthesia (IVIH). However, there remains controversy regarding the comparative effects of these three modalities on surgical field quality. IVIH, as an anesthetic strategy that integrates the advantages of both intravenous and inhalational agents, is widely employed in clinical practice. In the context of ESS, it may reduce the dose of individual agents through combination therapy, thereby minimizing dose-related adverse effects. Some studies have shown that propofol-based TIVA provides better surgical field conditions than inhalational anesthetics (e.g., desflurane, sevoflurane), but does not significantly reduce total blood loss or shorten operative time. Nevertheless, propofol is associated with drawbacks such as injection pain and propofol infusion syndrome. Fospropofol disodium, a water-soluble prodrug of propofol, offers a significant advantage in reducing injection pain and provides more stable hemodynamic profiles.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 12, 2026
Actual (reported)July 16, 2026
Actual (reported)August 26, 2026
Actual (reported)September 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The score of the Wormald scale
The Wormald scales was used to assess the quality of the surgical field, 0-10 points, with higher scores indicating worse visual field.
From the start of surgery to the end of surgery
The score of the Boezaart scale
The Boezaart scales was used to assess the quality of the surgical field, 0-5 points, with higher scores indicating worse visual field.
From the start of surgery to the end of surgery
Total blood loss
Perioperative
The rate of bleeding
Perioperative
Induction time
Perioperative
Extubation time
Perioperative
Emergence time
Perioperative
Propofol induction (1-2 mg/kg) and propofol maintenance (5-12 mg/kg/h).
Fospropofol disodium induction (10-20 mg/kg) and fospropofol disodium maintenance (5-12 mg/kg/h).
Propofol induction (1-2 mg/kg) and maintenance with propofol plus sevoflurane (1.0%).
Fospropofol disodium induction and fospropofol disodium maintenance with or without sevoflurane.
Propofol induction and propofol maintenance with or without sevoflurane.
Tongji Hospital
Wuhan, Hubei, 430030, China
Aihua Du, Dr
Tongji Hospital
First Submitted
July 16, 2026
First Posted
August 26, 2026
Study Start
July 12, 2026
Actual (reported)Primary Completion
September 30, 2026
Estimated (date passed)Fospropofol disodium induction (10-20 mg/kg) and maintenance with fospropofol disodium plus sevoflurane (1.0%).
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 17, 2026
Record last verified: 2026-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: